Overview
“At a time when biotechs are struggling to raise funds, the convergence with Artificial Intelligence technologies is attracting new investors who are more tech-savvy and less life science-oriented.”
Partner Anthony Paronneau explains the changes taking place and the challenges facing entrepreneurs at this crossroads in an interview with Jacques-Bernard Taste.
Click here to read the full article (in French via paywall).
